Louisa Rose Hoes
128 works · 2,289 citations · h-index 14
Top works
- Caring for patients with cancer in the COVID-19 era
- Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
- The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
- IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer
- Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
- Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
- Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
- Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
- Prospective experimental treatment of colorectal cancer patients based on organoid drug responses
- Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
- Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)
- Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
- Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4 /6 pathway alterations in the Dutch DRUP and Australian MoST trials
- LBA10 Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types
- The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
- Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
- Author Correction: Caring for patients with cancer in the COVID-19 era
- Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
- 1189O Validation of whole genome sequencing in routine clinical practice
- Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol